Adagene (ADAG) Competitors $2.09 -0.13 (-5.86%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ADAG vs. QNCX, IPHA, CGEN, CUE, XLO, DNA, AMLX, QTTB, CTNM, and CYRXShould you be buying Adagene stock or one of its competitors? The main competitors of Adagene include Quince Therapeutics (QNCX), Innate Pharma (IPHA), Compugen (CGEN), Cue Biopharma (CUE), Xilio Therapeutics (XLO), Ginkgo Bioworks (DNA), Amylyx Pharmaceuticals (AMLX), Q32 Bio (QTTB), Contineum Therapeutics (CTNM), and Cryoport (CYRX). Adagene vs. Quince Therapeutics Innate Pharma Compugen Cue Biopharma Xilio Therapeutics Ginkgo Bioworks Amylyx Pharmaceuticals Q32 Bio Contineum Therapeutics Cryoport Adagene (NASDAQ:ADAG) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings. Do analysts recommend ADAG or QNCX? Adagene presently has a consensus target price of $5.00, indicating a potential upside of 139.23%. Quince Therapeutics has a consensus target price of $8.50, indicating a potential upside of 361.96%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Does the MarketBeat Community believe in ADAG or QNCX? Adagene received 17 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Quince Therapeutics an outperform vote while only 80.77% of users gave Adagene an outperform vote. CompanyUnderperformOutperformAdageneOutperform Votes2180.77% Underperform Votes519.23%Quince TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Does the media favor ADAG or QNCX? In the previous week, Quince Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Quince Therapeutics and 0 mentions for Adagene. Adagene's average media sentiment score of 1.43 beat Quince Therapeutics' score of 0.92 indicating that Adagene is being referred to more favorably in the media. Company Overall Sentiment Adagene Positive Quince Therapeutics Positive Do insiders & institutionals believe in ADAG or QNCX? 9.5% of Adagene shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 16.8% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings & valuation, ADAG or QNCX? Adagene has higher revenue and earnings than Quince Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$815.75K113.43-$18.95MN/AN/AQuince TherapeuticsN/AN/A-$31.39M-$1.24-1.48 Which has more risk and volatility, ADAG or QNCX? Adagene has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Is ADAG or QNCX more profitable? Adagene's return on equity of 0.00% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Quince Therapeutics N/A -53.27%-22.73% SummaryQuince Therapeutics beats Adagene on 8 of the 15 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Adagene News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAG vs. The Competition Export to ExcelMetricAdagenePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.53M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.78126.3117.81Price / Sales113.43243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book1.305.474.684.68Net Income-$18.95M$153.61M$119.54M$226.08M7 Day Performance-9.91%-2.00%-1.83%-1.04%1 Month Performance-23.72%-7.46%-3.60%1.04%1 Year Performance54.81%31.82%31.91%26.28% Adagene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAGAdagene2.974 of 5 stars$2.09-5.9%$5.00+139.2%+52.6%$92.53M$815,746.000.00260News CoveragePositive NewsGap UpQNCXQuince Therapeutics2.8745 of 5 stars$1.84+4.0%$8.50+362.0%+109.1%$77.88MN/A0.0060IPHAInnate Pharma2.2362 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$120.64M$66.71M0.00220News CoverageGap UpCGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$128.50M$33.46M71.5068CUECue Biopharma4.4364 of 5 stars$1.09+0.9%$5.00+358.7%-55.3%$52.53M$5.49M0.0060Gap UpXLOXilio Therapeutics1.8842 of 5 stars$0.94-7.8%$4.00+325.0%-21.6%$44.84MN/A0.0073Gap DownDNAGinkgo Bioworks1.1347 of 5 stars$6.36-1.4%$4.58-28.1%N/A$358.46M$251.46M0.001,218Short Interest ↓AMLXAmylyx Pharmaceuticals4.3626 of 5 stars$5.23+0.2%$11.43+118.5%-59.5%$357.82M$380.79M0.00200Analyst UpgradeQTTBQ32 Bio1.6079 of 5 stars$27.28-6.2%$72.33+165.2%N/A$354.34M$1.16M0.0039CTNMContineum Therapeutics1.6382 of 5 stars$13.65+2.6%$29.25+114.3%N/A$342.85M$50M0.0031CYRXCryoport2.7225 of 5 stars$6.57-5.2%$12.50+90.3%-52.6%$342.80M$233.26M0.001,170Insider Trade Related Companies and Tools Related Companies QNCX Competitors IPHA Competitors CGEN Competitors CUE Competitors XLO Competitors DNA Competitors AMLX Competitors QTTB Competitors CTNM Competitors CYRX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADAG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adagene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
